Literature DB >> 29893702

Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014.

Samuel O Antwi1, Omar Y Mousa2, Tushar Patel2.   

Abstract

INTRODUCTION AND AIM: Despite reports of increased incidence of intrahepatic cholangiocarcinoma (iCCA) in the United States, the impact of age or influences of race and ethnicity are not clear. Disparities in iCCA outcomes across various population subgroups also are not readily recognized due to the rarity of this cancer. We examined ethnic, race, age, and gender variations in iCCA incidence and survival using data from the Surveillance, Epidemiology, and End Results Program (1995-2014).
MATERIAL AND METHODS: We assessed age-adjusted incidence rates, average annual percentage change in incidence, and hazard ratios (HRs) with 95% confidence intervals (CIs) for all-cause and iCCA-specific mortality.
RESULTS: Overall, 11,127 cases of iCCA were identified, with an age-adjusted incidence rate of 0.92 per 100,000. The incidence rate increased twofold, from 0.49 per 100,000 in 1995 to 1.49 per 100,000 in 2014, with an average annual rate of increase of 5.49%. The iCCA incidence rate was higher among persons age 45 years or older than those younger than 45 years (1.71 vs. 0.07 per 100,000), among males than females (0.97 vs. 0.88 per 100,000) and among Hispanics than non-Hispanics (1.18 vs. 0.89 per 100,000). Compared to non-Hispanics, Hispanics had poorer 5-year allcause mortality (HR = 1.11, 95%CI: 1.05-1.19) and poorer iCCA-specific mortality (HR = 1.15, 95%CI: 1.07-1.24). Survival rates were poor also for individuals age 45 years or older, men, and Blacks and American Indians/Alaska Natives.
CONCLUSION: The results demonstrate ethnic, race, age and gender disparities in iCCA incidence and survival, and confirm continued increase in iCCA incidence in the United States.

Entities:  

Keywords:  Ethnicity; Incidence; Intrahepatic cholangiocarcinoma; Race; SEER; Survival

Mesh:

Year:  2018        PMID: 29893702     DOI: 10.5604/01.3001.0012.0929

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  25 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Incidence and Prognosis of Subsequent Cholangiocarcinoma in Patients with Hepatic Resection for Bile Duct Stones.

Authors:  Hyun Jung Kim; Tae Uk Kang; Heather Swan; Min Ji Kang; Nayoung Kim; Hyeong Sik Ahn; Seon Mee Park
Journal:  Dig Dis Sci       Date:  2018-08-31       Impact factor: 3.199

3.  Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?

Authors:  Rachel M Lee; Yuan Liu; Adriana C Gamboa; Mohammad Y Zaidi; David A Kooby; Mihir M Shah; Kenneth Cardona; Maria C Russell; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2019-07-13       Impact factor: 3.454

4.  Increasing mortality of intrahepatic cholangiocarcinoma in the US: are gender-specific risk factors important?

Authors:  Samuel O Antwi; Tushar Patel
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

5.  Primary tumor resection improves survival in patients with multifocal intrahepatic cholangiocarcinoma based on a population study.

Authors:  Linlin Yin; Si Zhao; Hanlong Zhu; Guozhong Ji; Xiuhua Zhang
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

Review 6.  Repurposing metformin for the treatment of gastrointestinal cancer.

Authors:  Ademar Dantas Cunha Júnior; Arinilda Campos Bragagnoli; Felipe Osório Costa; José Barreto Campello Carvalheira
Journal:  World J Gastroenterol       Date:  2021-05-07       Impact factor: 5.742

7.  Cholangiocarcinoma in Pacific Islanders Compared to Asians.

Authors:  Jessica R Shiosaki; Tomoki Sempokuya; Brenda Y Hernandez; Linda L Wong
Journal:  Hawaii J Health Soc Welf       Date:  2021-02-01

8.  Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy.

Authors:  Jing Yu; Xi Zhang; Qiyue Huang; Sirui Tan; Xianze Xiong; Hongfeng Gou
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

9.  A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin.

Authors:  Kabir Mody; Samuel O Antwi; David O Hodge; Sikander Ailawadhi; Lewis Roberts; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2018-12

Review 10.  Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.

Authors:  Alphonse E Sirica; Gregory J Gores; John D Groopman; Florin M Selaru; Mario Strazzabosco; Xin Wei Wang; Andrew X Zhu
Journal:  Hepatology       Date:  2019-03-25       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.